Vericel (VCEL) Other financing activities (2010 - 2026)
Vericel (VCEL) posted Other financing activities of -$23000.0 for Q2 2026, down 9.52% sequentially from -$21000.0 in Q1 2026, and down 109.09% YoY from $253000.0 in Q2 2025.
Vericel (VCEL) Other financing activities (2010 - 2026) Analysis & Trends
Vericel has reported Other financing activities for 10 years, with the latest figure at -$23000.0 in Q2 2026.
- Quarterly Other financing activities fell 109.09% year-over-year to -$23000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$76000.0 (down 406.67% YoY) and the FY2025 annual result came in at -$47000.0, changed N/A from the prior year.
- Other financing activities slipped to -$23000.0 in Q2 2026 per VCEL's latest filing, from -$21000.0 in the prior quarter.
- Over five years, Other financing activities peaked at $3.7 million in Q4 2022 and troughed at -$23000.0 in Q2 2026.
- A 4-year average of $270769.2 and a median of -$19000.0 in 2022 frame the typical range for Other financing activities.
- The sharpest annual moves came in 2022 and 2026: Other financing activities jumped 148.89% in 2022, then slumped 425.0% in 2026.
- Over 4 years, Other financing activities stood at $3.7 million in 2022, then plunged by 100.57% to -$21000.0 in 2023, then changed by 0.0% to -$21000.0 in 2025, then fell by 9.52% to -$23000.0 in 2026.
- According to Business Quant data, Other financing activities over the past three periods registered -$23000.0, -$21000.0, and -$21000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Vericel | 2.26 Bn | 2.10 Bn | 56.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -23,000.00 |
| Jun 30, 2026 | -23,000.00 |
| Mar 31, 2026 | -21,000.00 |
| Mar 31, 2026 | -21,000.00 |
| Dec 31, 2025 | -21,000.00 |
| Dec 31, 2025 | -21,000.00 |
| Sep 30, 2025 | -11,000.00 |
| Sep 30, 2025 | -11,000.00 |
| Jun 30, 2025 | -11,000.00 |
| Jun 30, 2025 | -11,000.00 |
| Mar 31, 2025 | -4,000.00 |
| Mar 31, 2025 | -4,000.00 |
| Sep 30, 2023 | -21,000.00 |
| Sep 30, 2023 | -21,000.00 |
| Jun 30, 2023 | 1,000.00 |
| Jun 30, 2023 | 1,000.00 |
| Mar 31, 2023 | -21,000.00 |
| Mar 31, 2023 | -21,000.00 |
| Sep 30, 2022 | -21,000.00 |
| Sep 30, 2022 | -21,000.00 |